IGC Company Profile and Key Details

IGC Pharma, Inc. (AMEX:IGC) closed at $0.27 USD, losing -$0.01 (-2.32%) from the previous close of $0.27. The stock is currently mid-range between its 52-week high and low $0.24 and $0.50. With a market capitalization of about $26.19 million, IGC Pharma, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.31). Key stats such as the average daily volume over the past year has been around 361.08 thousand shares, volume is running light vs its 52-week average. Headquartered in Potomac, MD, IGC Pharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Ram Mukunda, the company employs approximately 67 people and listed since May 24, 2006. IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness.

IGC Pharma, Inc. trades at a P/E ratio of -4.72, slightly below the S&P 500 average, with a price-to-sales ratio of 21.84 and a price-to-book ratio of 3.39 trading at moderately above to book value. The P/FCF stands at -4.53, also below market averages.

IGC Pharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.45. This means the shares are trading below this model’s fair value.

IGC Pharma, Inc. generated EPS of -$0.08 over the past year. Five-year average earnings growth is 12.85%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $4.50. The high target offers 1751.85% upside. The low target suggests 1566.67% downside. The mean target is $4.75. This offers 1659.26% upside. IGC Pharma, Inc. earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by 0.0%. The prior quarter beat by -33.33%. Over the last six quarters, Apple has recorded several small beats. These include 15.38% in August 08, 2024.

IGC Pharma, Inc. has 90.91 million shares outstanding. The public float is 83.13 million shares, elevated short interest at 2.29% of float. This equals 1.33 million shares. The short ratio is 0.2 days. Institutional investors hold 20.26% of the float. Insiders own 8.45%. MUKUNDA RAM holds 2.77 million shares, UBS AG has 1.33 million shares and KRISHNA RANGA c has 1.07 million shares.

Short-term trend indicators are bullishly aligned (SMA20 7.89%, SMA50 -0.27%, SMA200 -16.54%). The stock’s 14-day RSI is 57.1 (neutral), while the ATR of 0.02 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -42.87% below its high and over 17.69% above its low. Average 10-day trading volume of 212.33 thousand shares is below the 3-month average of 339.14 thousand, indicating normal recent market interest.

IGC Pharma, Inc. (AMEX:IGC) shares are flat -0.46% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows IGC Pharma, Inc. trading at a premium to the broader market with a P/E of -4.72. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $4.00, suggesting 1408.86% upside. Our AI forecast model points to short-term weakness (-5.7% over two weeks), a medium-term rise (5.62% over three months), and a longer-term gain (2974.31% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that IGC Pharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.7%, with price expected at $0.25 by April 16, 2026, within a range of $0.24 to $0.26 3-Month Outlook: Projected rise of 5.62%, reaching $0.28 by July 01, 2026, with a range of $0.26 to $0.29. 1-Year Outlook: Projected gain of 2974.31%, with price at $8.15 by April 02, 2027, within a range of $2.88 to $11.48.